Redx Pharma PLC CEO Lisa Anson joins Proactive's Stephen Gunnion with details of a landmark partnership with Jazz Pharmaceuticals, marking its largest deal to date.
Anson explained the agreement involves the sale of Redx's KRAS programme, a key preclinical discovery initiative targeting genetic mutations driving various cancers. The $10 million upfront deal could potentially be followed by a further $870 million in milestone payments, signifying a major step forward for Redx in cancer research.
The KRAS programme focuses on combating hard-to-treat cancers, such as colorectal, lung, and pancreatic cancers, by targeting specific genetic mutations. The partnership aligns with RedX's strategy to balance in-house program development with collaborations that accelerate patient access to new treatments.
Anson emphasised the significance of partnerships in advancing their clinical-stage biotech research and development efforts. The deal not only provides immediate financing but also ensures Redx maintains a vested interest in the program's success through potential milestones and mid-single digit royalties on future sales.
Looking ahead, RedX anticipates a busy 2024 with several key milestones, including advancing its fibrosis and oncology programs, further demonstrating its commitment to addressing unmet medical needs.
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/redx-pharma-lands-biggest-deal-to-date-with-sale-of-kras-inhibitor-programme-to-jazz-pharma-706777108
Redx Pharma PLC
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Emerald Journal journalist was involved in the writing and production of this article.